CELG Share Price

Open 133.72 Change Price %
High 133.85 1 Day -3.00 -2.24
Low 130.78 1 Week -1.98 -1.49
Close 130.85 1 Month 14.07 12.05
Volume 4481723 1 Year 33.57 34.51
52 Week High 135.18
52 Week Low 96.93
CELG Important Levels
Resistance 2 133.70
Resistance 1 132.52
Pivot 131.83
Support 1 129.18
Support 2 128.00
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.22 0.00%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
QQQ 138.03 -1.81%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
SMSI 1.62 24.62%
CGEI 0.22 22.22%
THTI 0.20 17.65%
MYRX 0.07 16.67%
BDMS 13.50 16.38%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Celgene Corporation (NASDAQ: CELG)

CELG Technical Analysis 5
As on 27th Jun 2017 CELG Share Price closed @ 130.85 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 115.99 & Strong Buy for SHORT-TERM with Stoploss of 121.83 we also expect STOCK to react on Following IMPORTANT LEVELS.
CELG Target for June
1st Target up-side 120.46
2nd Target up-side 124.7
3rd Target up-side 128.94
1st Target down-side 108.36
2nd Target down-side 104.12
3rd Target down-side 99.88
CELG Other Details
Segment EQ
Market Capital 31326437376.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celgene.com
CELG Address
CELG
86 Morris Avenue
Summit, NJ 07901
United States
Phone: 908-673-9000
Fax: 908-673-9001
CELG Latest News
Interactive Technical Analysis Chart Celgene Corporation ( CELG NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Celgene Corporation
CELG Business Profile
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company’s primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics. The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland. REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.